Doyle Mittie has filed 33 insider transactions across 2 companies since July 2024.
Most recent transaction: a option exercise of 3000 shares of Avalo Therapeutics, Inc. ($AVTX) on May 15, 2026.
Activity breakdown: 0 open-market purchases and 10 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 15, 2026 | Avalo Therapeutics, Inc. | $AVTX | Doyle Mittie | Chief Medical Officer | M | Common Stock | 3000 | $12.65 | 6,622.0000 | 18,133,968 | 82.83% | 0.02% |
| May 15, 2026 | Avalo Therapeutics, Inc. | $AVTX | Doyle Mittie | Chief Medical Officer | M | Stock Option (Right to Buy) | 3000 | $0.00 | 128,625.0000 | 18,133,968 | 2.28% | 0.02% |
| May 15, 2026 | Avalo Therapeutics, Inc. | $AVTX | Doyle Mittie | Chief Medical Officer | S | Common Stock | 3000 | $18.76 | 3,622.0000 | 18,133,968 | 45.30% | 0.02% |
| May 5, 2026 | Avalo Therapeutics, Inc. | $AVTX | Doyle Mittie | Chief Medical Officer | M | Common Stock | 1000 | $12.65 | 4,622.0000 | 18,133,968 | 27.61% | 0.01% |
| May 5, 2026 | Avalo Therapeutics, Inc. | $AVTX | Doyle Mittie | Chief Medical Officer | M | Common Stock | 679 | $8.04 | 5,301.0000 | 18,133,968 | 14.69% | 0.00% |
| May 5, 2026 | Avalo Therapeutics, Inc. | $AVTX | Doyle Mittie | Chief Medical Officer | S | Common Stock | 1679 | $16.00 | 3,622.0000 | 18,133,968 | 31.67% | 0.01% |
| May 6, 2026 | Avalo Therapeutics, Inc. | $AVTX | Doyle Mittie | Chief Medical Officer | M | Common Stock | 77905 | $12.65 | 81,527.0000 | 18,133,968 | 2150.88% | 0.43% |
| May 6, 2026 | Avalo Therapeutics, Inc. | $AVTX | Doyle Mittie | Chief Medical Officer | M | Common Stock | 28650 | $8.04 | 110,177.0000 | 18,133,968 | 35.14% | 0.16% |
| May 6, 2026 | Avalo Therapeutics, Inc. | $AVTX | Doyle Mittie | Chief Medical Officer | S | Common Stock | 27538 | $18.03 | 82,639.0000 | 18,133,968 | 24.99% | 0.15% |
| May 6, 2026 | Avalo Therapeutics, Inc. | $AVTX | Doyle Mittie | Chief Medical Officer | S | Common Stock | 5000 | $19.65 | 77,639.0000 | 18,133,968 | 6.05% | 0.03% |
| May 6, 2026 | Avalo Therapeutics, Inc. | $AVTX | Doyle Mittie | Chief Medical Officer | S | Common Stock | 44944 | $21.20 | 32,695.0000 | 18,133,968 | 57.89% | 0.25% |
| May 6, 2026 | Avalo Therapeutics, Inc. | $AVTX | Doyle Mittie | Chief Medical Officer | S | Common Stock | 19015 | $22.41 | 13,680.0000 | 18,133,968 | 58.16% | 0.10% |
| May 6, 2026 | Avalo Therapeutics, Inc. | $AVTX | Doyle Mittie | Chief Medical Officer | S | Common Stock | 10058 | $22.88 | 3,622.0000 | 18,133,968 | 73.52% | 0.06% |
| May 5, 2026 | Avalo Therapeutics, Inc. | $AVTX | Doyle Mittie | Chief Medical Officer | M | Stock Option (Right to Buy) | 1000 | $0.00 | 209,530.0000 | 18,133,968 | 0.47% | 0.01% |
| May 5, 2026 | Avalo Therapeutics, Inc. | $AVTX | Doyle Mittie | Chief Medical Officer | M | Stock Option (Right to Buy) | 679 | $0.00 | 147,650.0000 | 18,133,968 | 0.46% | 0.00% |
| May 6, 2026 | Avalo Therapeutics, Inc. | $AVTX | Doyle Mittie | Chief Medical Officer | M | Stock Option (Right to Buy) | 77905 | $0.00 | 131,625.0000 | 18,133,968 | 37.18% | 0.43% |
| May 6, 2026 | Avalo Therapeutics, Inc. | $AVTX | Doyle Mittie | Chief Medical Officer | M | Stock Option (Right to Buy) | 28650 | $0.00 | 119,000.0000 | 18,133,968 | 19.40% | 0.16% |
| April 6, 2026 | Avalo Therapeutics, Inc. | $AVTX | Doyle Mittie | Chief Medical Officer | M | Stock Option (Right to Buy) | 3970 | $0.00 | 210,530.0000 | 18,133,968 | 1.85% | 0.02% |
| April 6, 2026 | Avalo Therapeutics, Inc. | $AVTX | Doyle Mittie | Chief Medical Officer | M | Common Stock | 3970 | $12.65 | 7,592.0000 | 18,133,968 | 109.61% | 0.02% |
| April 6, 2026 | Avalo Therapeutics, Inc. | $AVTX | Doyle Mittie | Chief Medical Officer | S | Common Stock | 3970 | $18.01 | 3,622.0000 | 18,133,968 | 52.29% | 0.02% |
| April 1, 2026 | Avalo Therapeutics, Inc. | $AVTX | Doyle Mittie | Chief Medical Officer | S | Common Stock | 679 | $16.00 | 3,622.0000 | 18,133,968 | 15.79% | 0.00% |
| April 1, 2026 | Avalo Therapeutics, Inc. | $AVTX | Doyle Mittie | Chief Medical Officer | M | Common Stock | 679 | $8.04 | 4,301.0000 | 18,133,968 | 18.75% | 0.00% |
| April 1, 2026 | Avalo Therapeutics, Inc. | $AVTX | Doyle Mittie | Chief Medical Officer | M | Stock Option (Right to Buy) | 679 | $0.00 | 148,329.0000 | 18,133,968 | 0.46% | 0.00% |
| March 16, 2026 | Avalo Therapeutics, Inc. | $AVTX | Doyle Mittie | Chief Medical Officer | M | Common Stock | 5992 | $8.04 | 29,114.0000 | 18,133,968 | 25.91% | 0.03% |
| March 16, 2026 | Avalo Therapeutics, Inc. | $AVTX | Doyle Mittie | Chief Medical Officer | S | Common Stock | 25492 | $16.15 | 3,622.0000 | 18,133,968 | 87.56% | 0.14% |
| March 16, 2026 | Avalo Therapeutics, Inc. | $AVTX | Doyle Mittie | Chief Medical Officer | M | Common Stock | 19500 | $12.65 | 23,122.0000 | 18,133,968 | 538.38% | 0.11% |
| March 16, 2026 | Avalo Therapeutics, Inc. | $AVTX | Doyle Mittie | Chief Medical Officer | M | Stock Option (Right to Buy) | 5992 | $0.00 | 149,008.0000 | 18,133,968 | 3.87% | 0.03% |
| March 16, 2026 | Avalo Therapeutics, Inc. | $AVTX | Doyle Mittie | Chief Medical Officer | M | Stock Option (Right to Buy) | 19500 | $0.00 | 214,500.0000 | 18,133,968 | 8.33% | 0.11% |
| Feb. 26, 2026 | Avalo Therapeutics, Inc. | $AVTX | Doyle Mittie | Chief Medical Officer | A | Stock Option (Right to Buy) | 105000 | $0.00 | 105,000.0000 | 18,133,968 | 9999.99% | 0.58% |
| Dec. 10, 2025 | Avalo Therapeutics, Inc. | $AVTX | Doyle Mittie | Chief Medical Officer | F | Common Stock | 1013 | $4.10 | 3,622.0000 | 18,133,968 | 21.86% | 0.01% |
| Aug. 7, 2025 | Cullinan Therapeutics, Inc. | $CGEM | Doyle Mittie | Not found | A | Stock Option (Right to Buy) | 79456 | $0.00 | 79,456.0000 | 58,510,610 | 9999.99% | 0.14% |
| Jan. 28, 2025 | Avalo Therapeutics, Inc. | $AVTX | Doyle Mittie | Chief Medical Officer | A | Stock Option (Right to Buy) | 155000 | $0.00 | 155,000.0000 | 0 | 9999.99% | 0.00% |
| July 15, 2024 | Avalo Therapeutics, Inc. | $AVTX | Doyle Mittie | Chief Medical Officer | A | Stock Option (Right to Buy) | 234000 | $0.00 | 234,000.0000 | 0 | 9999.99% | 0.00% |